Innodem Neurosciences

Innodem Neurosciences is a digital biomarker & AI company that specializes in the development of an eye tracking technology, ETNA™, that shows promising use for neurological assessment of the progression of various neurodegenerative and mental diseases. Paul Giacomini is a neurologist with post-doctoral studies conducted at McGill University. Yves Desgagné is a software engineer & AI expert and the former Director of R&D at Verint Systems and a founding member of Innodem Neurosciences. Patrice Voss leads all neurosciences research at Innodem Neurosciences and is a Research Associate at the Montreal Neuro Hospital, a McGill University affiliate entity. Innodem Neurosciences, a leading digital biomarker & AI company. Innodem, a company led by a team of neurologists, neuroscientists, AI experts, data scientists, and software engineers, has patented its newly developed technology in North America, Europe, and Asia. The company’s ongoing pipeline of clinical trials in various neurodegenerative disorders provides well-phenotyped patient data that is ingested by various machine learning algorithms to train them to improve predictability models. A gaze mapping biomarker, or GMB, is a quantitative measure of human cognition that analyzes the gaze patterns produced while performing short visual tasks.